vs
Assertio Holdings, Inc.（ASRT）与Forian Inc.（FORA）财务数据对比。点击上方公司名可切换其他公司
Assertio Holdings, Inc.的季度营收约是Forian Inc.的1.7倍（$13.5M vs $8.0M），Forian Inc.同比增速更快（37.0% vs -57.9%），过去两年Forian Inc.的营收复合增速更高（27.8% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
Forian Inc是一家专注于医疗健康领域的数据分析与技术服务商，提供SaaS模式的真实世界证据解决方案、临床决策支持工具及运营优化服务，客户覆盖生物制药企业、医疗机构及生命科学领域相关机构，助力提升诊疗效率、推动医学研究进展。
ASRT vs FORA — 直观对比
营收规模更大
ASRT
是对方的1.7倍
$8.0M
营收增速更快
FORA
高出94.9%
-57.9%
两年增速更快
FORA
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $8.0M |
| 净利润 | — | $-1.8M |
| 毛利率 | — | 49.2% |
| 营业利润率 | -86.7% | -24.4% |
| 净利率 | — | -22.9% |
| 营收同比 | -57.9% | 37.0% |
| 净利润同比 | — | -1012.2% |
| 每股收益（稀释后） | $-4.54 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTFORA
| Q4 25 | $13.5M | $8.0M | ||
| Q3 25 | $49.5M | $7.8M | ||
| Q2 25 | $29.2M | $7.5M | ||
| Q1 25 | $26.5M | $7.1M | ||
| Q4 24 | $32.2M | $5.8M | ||
| Q3 24 | $29.2M | $4.7M | ||
| Q2 24 | $31.1M | $4.8M | ||
| Q1 24 | $32.4M | $4.9M |
净利润ASRTFORA
| Q4 25 | — | $-1.8M | ||
| Q3 25 | $11.4M | $-151.2K | ||
| Q2 25 | $-16.4M | $224.8K | ||
| Q1 25 | $-13.5M | $-1.1M | ||
| Q4 24 | — | $199.7K | ||
| Q3 24 | $-2.9M | $-204.9K | ||
| Q2 24 | $-3.7M | $-2.6M | ||
| Q1 24 | $-4.5M | $-1.2M |
毛利率ASRTFORA
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 51.6% | ||
| Q2 25 | — | 56.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 58.3% | ||
| Q3 24 | — | 70.1% | ||
| Q2 24 | — | 62.2% | ||
| Q1 24 | — | 65.1% |
营业利润率ASRTFORA
| Q4 25 | -86.7% | -24.4% | ||
| Q3 25 | 23.2% | -6.1% | ||
| Q2 25 | -27.5% | 0.6% | ||
| Q1 25 | -50.0% | -19.8% | ||
| Q4 24 | -41.9% | -24.9% | ||
| Q3 24 | -10.4% | -17.0% | ||
| Q2 24 | -11.6% | -62.2% | ||
| Q1 24 | -13.4% | -36.3% |
净利率ASRTFORA
| Q4 25 | — | -22.9% | ||
| Q3 25 | 23.1% | -1.9% | ||
| Q2 25 | -56.0% | 3.0% | ||
| Q1 25 | -51.1% | -16.0% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | -10.0% | -4.4% | ||
| Q2 24 | -11.8% | -53.4% | ||
| Q1 24 | -13.9% | -24.9% |
每股收益（稀释后）ASRTFORA
| Q4 25 | $-4.54 | $-0.06 | ||
| Q3 25 | $0.11 | $0.00 | ||
| Q2 25 | $-0.17 | $0.01 | ||
| Q1 25 | $-0.14 | $-0.04 | ||
| Q4 24 | $-3.28 | $0.01 | ||
| Q3 24 | $-0.03 | $-0.01 | ||
| Q2 24 | $-0.04 | $-0.08 | ||
| Q1 24 | $-0.05 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | $31.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $94.0M | $29.8M |
| 总资产 | $267.0M | $44.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASRTFORA
| Q4 25 | $63.4M | $31.6M | ||
| Q3 25 | $93.4M | $28.2M | ||
| Q2 25 | $98.2M | $35.6M | ||
| Q1 25 | $87.3M | $35.7M | ||
| Q4 24 | $100.1M | $35.1M | ||
| Q3 24 | $88.6M | $49.4M | ||
| Q2 24 | $88.4M | $48.0M | ||
| Q1 24 | $80.7M | $47.4M |
总债务ASRTFORA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $38.6M | — |
股东权益ASRTFORA
| Q4 25 | $94.0M | $29.8M | ||
| Q3 25 | $105.8M | $31.1M | ||
| Q2 25 | $93.3M | $30.9M | ||
| Q1 25 | $108.5M | $30.0M | ||
| Q4 24 | $121.1M | $30.1M | ||
| Q3 24 | $130.5M | $28.4M | ||
| Q2 24 | $132.2M | $27.2M | ||
| Q1 24 | $134.5M | $28.1M |
总资产ASRTFORA
| Q4 25 | $267.0M | $44.1M | ||
| Q3 25 | $319.8M | $41.3M | ||
| Q2 25 | $273.8M | $48.5M | ||
| Q1 25 | $286.4M | $48.6M | ||
| Q4 24 | $284.7M | $47.2M | ||
| Q3 24 | $276.0M | $57.5M | ||
| Q2 24 | $279.4M | $58.4M | ||
| Q1 24 | $282.0M | $57.5M |
负债/权益比ASRTFORA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $3.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASRTFORA
| Q4 25 | $-30.0M | $3.2M | ||
| Q3 25 | $-4.8M | $-439.7K | ||
| Q2 25 | $19.1M | $-344.5K | ||
| Q1 25 | $-12.5M | $448.2K | ||
| Q4 24 | $11.5M | $1.7M | ||
| Q3 24 | $-35.0K | $764.1K | ||
| Q2 24 | $7.4M | $-23.1K | ||
| Q1 24 | $7.5M | $-2.2M |
资本支出强度ASRTFORA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率ASRTFORA
| Q4 25 | — | — | ||
| Q3 25 | -0.42× | — | ||
| Q2 25 | — | -1.53× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 8.76× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
FORA
| Financial Services Revenues | $7.3M | 92% |
| Other | $669.0K | 8% |
